NCT07903493
Phase Ia Study of MST-931 in Healthy Adult Subjects
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Percentage of subjects with drug related adverse events (AEs)
Timeframe: Through study completion, up to 113 days
Secondary (4)
PK parameters for MST-931: Area Under Curve (AUC)
PK parameters for MST-931: Maximum Observed Concentration (Cmax)
PK parameters for MST-931: Time of maximum observed concentration (Tmax)
PK parameters for MST-931: Elimination Half-life (t1/2)
Arms and interventions
MST-931 dose level 1 treatment CohortExperimental
MST-931 dose level 1
MST-931 dose level 2 treatment CohortExperimental
MST-931 dose level 2
MST-931 dose level 3 treatment CohortExperimental
MST-931 dose level 3
MST-931 dose level 4 treatment CohortExperimental
MST-931 dose level 4
Matching placebo for each dose groupPlacebo comparator
Matching placebo
Biologicals: MST-931, MST-931 Placebo
Sites
1 site in 1 country
- Q-Pharm Pty LtdHerston, Queensland, Australia